Comparative Pharmacology
Head-to-head clinical analysis: FORBAXIN versus NEO FRADIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORBAXIN versus NEO FRADIN.
FORBAXIN vs NEO-FRADIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
IV: 500 mg every 12 hours, infused over 30 minutes.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
None Documented
None Documented
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Category C
Category C
Antibiotic
Antibiotic